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OBJECTIVES Isoprostanes, stable end-products of oxygen free radical mediated–lipid peroxidation, were
measured in the coronary vessels during percutaneous transluminal coronary angioplasty
(PTCA) to provide direct evidence for enhanced oxidative stress in a local milieu in vivo.
BACKGROUND Percutaneous transluminal coronary angioplasty is associated with complications such as
myocardial stunning and accelerated restenosis, which at least in part are mediated by oxygen
free radicals. Because isoprostanes are markers of oxidant stress and potent vasoactive
compounds, the formation of which is not inhibited by aspirin treatment in vivo, it is possible
that these mediators are increased locally during PTCA.
METHODS In 12 coronary artery disease patients who were given aspirin and ticlopidine, blood samples
from coronary sinus were taken immediately before and immediately upon balloon deflation
during PTCA. Isoprostane F2a-III, isoprostane F2a-VI, and TxB2 were quantified after
extraction and chromatography using a stable dilution isotope gas chromatography/mass
spectrometry assay.
RESULTS Coronary sinus and left main coronary artery levels of iPF2a-III and iPF2a-VI at baseline
were (mean 6 SEM) 40 6 9 pg/ml and 115 6 10 pg/ml, respectively. The TxB2 levels were
undetectable. Following PTCA, isoprostane levels markedly increased (mean 6 SEM):
iPF2a-III, 125 6 12 pg/ml (p , 0.001); iPF2a-VI, 295 6 20 pg/ml (p , 0.001), whereas
TxB2 levels remained undetectable.
CONCLUSIONS These results indicate that PTCA induces coronary sinus increase in F2-isoprostane
formation, and they also provide direct evidence for enhanced oxidative stress in a local milieu
in vivo. Thus, an increased F2-isoprostane formation could play a role in the pathogenesis of
some PTCA-associated untoward events. (J Am Coll Cardiol 2001;37:76–80) © 2001 by
the American College of Cardiology
Percutaneous transluminal coronary angioplasty (PTCA) is
a widely used and effective method to restore coronary flow
in patients with symptomatic coronary artery disease (1). It
is known that restoration of coronary flow may also ad-
versely affect myocardium by inducing effects such as myo-
cardial stunning and arrhythmogenesis (2,3). Such effects
have been well documented in animal studies and are
probably mediated by oxygen free radicals (OFR) (4). In
these models, OFR scavenging agents reduce the severity of
myocardial injury (5–8). However, how these models relate
to human studies is still uncertain. Some studies have shown
the formation of OFR after PTCA in humans (9,10).
Others, however, have not found an increase in the levels of
lipid products during PTCA (11).
Isoprostanes (iPs) are prostaglandin isomers formed by
free radical-catalyzed oxidation of arachidonic acid esterified
in membrane phospholipids (12). They represent chemically
stable end products of lipid peroxidation that circulate in
plasma and are excreted in urine (13). Measurement of iPs
may be a sensitive and specific index of oxidant stress in
vivo. Levels of iPs are increased in animal models of
OFR-mediated injury as well as in humans in diverse
settings in which OFR-mediated tissue damage is strongly
implicated (14–16). Recently, it has been reported that iPs
generation is increased in syndromes of coronary reperfusion
(17). Moreover, iPs are significantly increased in urine of
patients undergoing acute PTCA for myocardial infarction,
whereas only a slight increase was observed in patients
undergoing elective PTCA (18). However, it is still not
known whether iPs are increased in vivo locally in the
coronary arteries during PTCA.
A peculiar characteristic of these isoeicosanoids is that
they also possess biological activities. Thus, a member of the
F2-iPs family, 8-iso prostaglandin F2a, now known as
iPF2a-III (19), is a potent mitogen for smooth muscle cells,
causes vasoconstriction in bovine and porcine coronary
arteries and increases platelet activation and adhesion (20–
23).
Because of the potential importance of iPs as markers of
oxidant stress in vivo and as biological active compounds on
the vasculature, and in view of the PTCA-related sequelae
such as coronary vasospasm, we monitored the coronary
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sinus levels of two distinct iPs within the framework of
elective PTCA.
METHODS
Patients. Twelve consecutive subjects (mean age 57 years;
range 45 to 70 years) were enrolled with the following
characteristics: 1) stable angina pectoris with an exercise
treadmill test positive for ischemia within the preceding six
months; 2) single-vessel coronary artery defined as .70%
stenosis in left anterior descending coronary artery deemed
approachable by PTCA on previous diagnostic coronary
angiography; 3) lack of angiographic features suggestive of
an “active” lesion (defined as a lesion with an intracoronary
filling defect suggestive of stenosis-related thrombus); and
4) no conduction defects on the electrocardiogram (ECG).
All patients were taking aspirin (160 mg/day) for at least
four weeks before the procedure, and ticlopidine
(500 mg/day) for at least 48 h before the procedure. Other
medications for the treatment of angina pectoris (calcium
channel blockers, beta-blockers and nitrates) were contin-
ued. As controls, four patients (all men, mean age 58 years;
range 46 to 70 years) undergoing cardiac catheterization for
valvular heart disease with no coronary lesions were also
studied. The study was approved by the ethical committee
of the hospital board, and all patients signed an informed
consent.
PTCA and sample acquisition. All 12 patients underwent
PTCA via a femoral approach. Briefly, they were premed-
icated with diazepam and diphenhyldramine. Heparin
(5,000 IU) was given as a bolus at the beginning of the
procedure and additional boluses were injected if necessary
to maintain an activated coagulation time $250 s. Diag-
nostic coronary angiography was performed using a non-
ionic contrast media (Omnipaque, Nycomed Imaging AS).
Five contrast injections in different X-ray projections were
used for the left coronary artery and two contrast injections
for the right coronary artery (total 42 ml of nonionic
contrast media). At the end of the diagnostic procedure, a
6F NIH catheter was positioned in the distal coronary sinus
via the right internal jugular vein, and a 7F Judkins guide
catheter was positioned in the ostium of the left main
coronary artery to start the PTCA. For each patient, basal
contemporary samples were obtained at this time from the
coronary sinus and from the left main coronary artery. After
flushing with saline and discarding 5 ml of blood, from each
catheter a 10-ml sample was withdrawn into a second
syringe containing heparin (500 IU/ml) and EDTA (2
mmol/liter). The EDTA was used to prevent the artifactual
generation of eicosanoids during the sampling procedure.
Next, the intracoronary wire was positioned distally in the
left anterior descending artery, and the balloon catheter was
advanced across the stenosis and inflated for 120 s at the
nominal balloon inflating pressure. Immediately upon bal-
loon deflation, after flushing with saline and discarding 5 ml
of blood, a 10-ml blood sample was taken from the coronary
sinus catheter as was done with the first sample. There were
no acute vessel closures and no patients experienced com-
plicating myocardial infarction, or significant bleeding.
There were no stent implantations. Coronary angiography
was then performed to ensure a satisfactory angioplasty
result.
Patients undergoing diagnostic coronary angiography be-
fore valvular replacement operation were studied as controls.
Blood samples were taken from the coronary sinus and the
left main coronary artery after the performance of coronary
angiography. No complications related to the procedure
occurred.
Analyses were performed without knowledge of the
location within the coronary artery from which the blood
originated.
Biochemical analysis. Blood samples were centrifuged at
3,000 rpm for 10 min. Plasma was collected and added with
10 mg [2H8]-arachidonic acid in order to detect any arti-
factual formation of the isoprostanes of interest, then stored
at 280°C. Samples were shipped in dry ice and received
within 24 h. Artifactual generation of iPs was monitored by
measuring formation of [2H8]-iPF2a-III or [
2H8]-iPF2a-
VI. All of the gas chromatography/mass spectrometry
(GC/MS) analyses were performed on a Fisons MD-800
mass spectrometer interfaced with a Fisons 800 GC and an
AS-800 autosampler as previously described (15–18,24).
The mass spectrometer was operated in the negative ion
chemical ionization mode using ammonia as the moderating
gas (15–18,24). Standard validation criteria as well as
interassay and intra-assay variability for all the following
methodology described have been reported elsewhere (24–
26). The iPF2a-III was analyzed as pentafluorylbenzyl ester
(PFB)/ter-butyldimethylsilyl ether derivative (15–
18,24,25), while iPF2a-VI was analyzed as PFB/
trimethylsilyl ether derivative (24,25). TxA2, measured as its
stable hydrolysis product TxB2, was analyzed as the PFB/
trimethylsilyl ether derivative as previously described
(24,26,27).
Statistical analysis. All data are expressed as mean 6
SEM. Data were compared by use of appropriate t-test for
paired data, and by a one-way analysis of variance. Simple
regression analysis was performed to analyze the relation
between iPF2a-III and iPF2a-VI. Differences were consid-




OFR 5 oxygen free radicals
PFB 5 pentafluorybenzyl
PTCA 5 percutaneous transluminal coronary
angioplasty
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RESULTS
Twelve patients underwent elective PTCA. The clinical
characteristics of the population study are described in
Table 1. Ten patients had a history of cigarette smoking,
two had high blood pressure, eight had total plasma
cholesterol levels greater than 200 mg/dl, and four had type
II diabetes mellitus. No complications were encountered
during PTCA. Angiography of the target coronary artery
immediately after postdeflation sample acquisition showed
no significant residual stenosis with normal contrast runoff.
Table 2 reports on the levels of TxB2, iPF2a-III and
iPF2a-VI at baseline in patients undergoing PTCA. Sam-
ples taken from the coronary sinus before the balloon
inflation had TxB2 values below the detection limit of the
assay (Table 2). Levels of iPF2a-III and iPF2a-VI were
40 6 9 and 115 6 10 pg/ml, respectively (Table 2). By
measuring [2H8]-iPF2a-III or [
2H8]-iPF2a-VI levels in
each sample (data not shown), no artifactual generation of
iPs was detected. To assess whether the site of the sampling
in the coronary artery was important for the baseline values
observed, additional samples were taken from the left
coronary artery. No significant difference in iPs and TxB2
levels was observed between samples taken from the coro-
nary sinus or the left coronary artery (Table 2). In contrast,
all of the post-PTCA samples taken from the coronary sinus
showed increased amounts (mean 6 SEM) of both iPF2a-
III (125 6 12 pg/ml, p , 0.001) and iPF2a-VI (295 6 20
pg/ml, p , 0.001) (Fig. 1). No increase in TxB2 was
detected in any of the subjects after PTCA, indicating that
aspirin had completely suppressed platelet cyclooxygenase
enzyme activity in these patients. A significant correlation
existed between the levels of the two iPs (r 5 0.68, p ,
0.05).
To assess the potential contribution of the catheter per se
during angiography, we monitored the coronary levels of iPs
in four patients undergoing cardiac catheterization for
valvular heart disease. At the end of the diagnostic proce-
dure, two samples from these patients were collected, one in
the coronary sinus and one in the left main coronary artery,
as was done for the cohort of PTCA patients. Levels of the
two iPs were similar to the levels observed in the patients
undergoing PTCA at baseline before balloon inflation
(Table 3).
DISCUSSION
Isoprostanes and PTCA. The iPs are prostaglandin iso-
mers formed by a free radical catalyzed attack of
phospholipid-containing arachidonic acid in situ in mem-
Figure 1. Coronary sinus levels of iPF2a-III (A) and iPF2a-VI (B) before
and after elective PTCA (n 5 12). *p , 0.001.
Table 1. Clinical Characteristics of the Patients Undergoing
PTCA
Total population (n) 12
Age (years) (mean 6 SD) 57 6 8
Men (n) 11
Cigarette smoking (n) 10
Diabetes mellitus (n) 4
High blood pressure (.200 mg/dl) (n) 2
High cholesterol (n) 8
Previous MI (n) 6
Positive ETT (n) 12
ETT 5 exercise treadmill test within six months before PTCA; MI 5 myocardial
infarction; PTCA 5 percutaneous transluminal coronary angioplasty.
Table 2. Levels of TxB2, iPF2a-III and iPF2a-VI in the





Artery (n 5 12) p
TxB2 (ng/ml) ND ND —
iPF2a-III (pg/ml) 40 6 9 45 6 12 NS
iPF2a-VI (pg/ml) 115 6 10 105 6 12 NS
ND 5 not detectable; NS 5 not significant.
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branes (28). They are stable end products of lipid peroxi-
dation that offer advantages over other indices of lipid
peroxidation used thus far. They are formed in vivo, possess
potent biological activities, circulate in plasma and are
excreted in urine (12,13). We and other investigators have
demonstrated that iPs are sensitive and specific markers of
lipid peroxidation and oxidative stress in vivo (14–17,29).
Recently, it has been reported that systemic increase of iPs
in patients undergoing acute PTCA for myocardial infarc-
tion has been reported (17,18). The present investigation
extends these findings, as no data are available on the iPs
levels in the coronary vessels during this procedure. In this
study we demonstrate for the first time that angioplasty is
associated with an increase in iPs levels in the coronary
sinus. Samples taken before balloon inflation revealed only
discrete levels of iPF2a-III and iPF2a-VI in the coronary
circulation. In contrast, samples taken after PTCA at the
coronary sinus contained significantly increased levels of
both types of iPs, which were highly correlated. The specific
role of balloon inflation during PTCA in inducing this
increase was further supported by the iPs levels found in
control patients undergoing diagnostic coronary angiogra-
phy. In fact, these patients at the end of coronary angiog-
raphy had iPs levels in the left main coronary artery and in
the coronary sinus comparable to baseline values of patients
before undergoing PTCA. However, we cannot exclude the
theoretical possibility of a “stress” related to the performance
of PTCA, which caused a systemic rise in iPs levels, as we
did not take a sample from the left coronary ostium after
balloon deflation.
Percutaneous transluminal coronary angioplasty is a well-
established method of restoring coronary flow in patients
with symptomatic coronary artery disease (1), and it can be
considered as an in vivo model of ischemia-reperfusion
injury. The increased level of the two iPs in patients
undergoing elective PTCA is consistent with the hypothe-
sis that generation of these compounds reflects a com-
mon OFR-dependent pathway as a result of ischemia-
reperfusion chemistry.
Eicosanoids and PTCA. Several studies have provided
evidence for increased formation of eicosanoids during
PTCA. For example, thromboxane generation by activated
platelet during PTCA is at least in part considered respon-
sible for the vasoconstriction (30,31). However, in a signif-
icant number of patients, aspirin, at a dosage that inhibits
TxB2 formation, does not prevent PTCA-induced vaso-
spasm (32). Similarly, restenosis after PTCA has not been
shown to be influenced by aspirin (33,34). These data
suggest that mediators not inhibited by aspirin may also play
a role in some of the complications of PTCA. The finding
that PTCA triggers an increase in coronary sinus isopros-
tane levels, whose actions are not inhibited by aspirin,
provides further insight into the pathophysiology of PTCA-
induced vasospasm and may have important implications in
patients undergoing interventions that produce coronary
vascular injury. Interestingly, intracoronary administration
of iPF2a-III has been shown to cause in vitro vasoconstric-
tion in porcine and bovine coronary arteries with an EC50 of
0.5 and 1 mmol/liter, respectively (21). These concentra-
tions are similar to the intracoronary levels of iPF2a-III that
we found after PTCA. Thus, the constriction often ob-
served in the distal segment of the instrumented vessel
might be due to the formation and translocation “down-
stream” of this vasoactive prostaglandin isomer formed as
result of oxidative stress.
Furthermore, PTCA-induced plaque rupture with the
exposure of cellular constituents it is known to increase in
vivo platelet activation and adhesion, which may play a role
in some of the sequelae of this procedure. It has been
reported that iPF2a-III increases in vitro platelet activation
and adhesion with a EC50 similar to the one reported above,
and that both effects are prevented by thromboxane receptor
antagonist but not by aspirin (22,23). Thus, we suggest that
this isoeicosanoid should be added to the complex list of
biologically active compounds formed after PTCA.
Conclusions. The present investigation demonstrates for
the first time an increase in iPs generation, markers of in
vivo lipid peroxidation and oxidative stress, in the coronary
sinus of patients after elective PTCA. Considering that
their formation and biological activities are aspirin-
insensitive and that the coronary sinus levels reached after
PTCA are close to the ones that provoke coronary artery
constriction in animals and increase human platelet activa-
tion and adhesion, we conclude that iPs could play a role in
the untoward events of this procedure such as vasospasm.
Further studies to assess the mechanism of PTCA-induced
release of iPs as well as the impact of pharmacological
interventions are warranted.
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